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Abstract. It is an open issue whether blood biomarkers serve to diagnose Alzheimer’s disease (AD) or monitor its pro-
gression over time from prodromal stages. Here, we addressed this question starting from data of the European FP7
IMI-PharmaCog/E-ADNI longitudinal study in amnesic mild cognitive impairment (aMCI) patients including biological,
clinical, neuropsychological (e.g., ADAS-Cog13), neuroimaging, and electroencephalographic measures. PharmaCog/E-
ADNI patients were classified as “positive” (i.e., “prodromal AD”; n = 76) or “negative” (n = 52) based on a diagnostic
cut-off of A42/P-tau in cerebrospinal fluid as well as APOE 4 genotype. Blood was sampled at baseline and at two follow-
ups (12 and 18 months), when plasma amyloid peptide 42 and 40 (A42, A40) and apolipoprotein J (clusterin, CLU) were
assessed. Linear Mixed Models found no significant differences in plasma molecules between the “positive” (i.e., prodromal
AD) and “negative” groups at baseline. In contrast, plasma A42 showed a greater reduction over time in the prodromal AD
than the “negative” aMCI group (p = 0.048), while CLU and A40 increased, but similarly in the two groups. Furthermore,
plasma A42 correlated with the ADAS-Cog13 score both in aMCI patients as a whole and the prodromal AD group alone.
Finally, CLU correlated with the ADAS-Cog13 only in the whole aMCI group, and no association with ADAS-Cog13 was
found for A40. In conclusion, plasma A42 showed disease progression-related features in aMCI patients with prodromal
AD.
Keywords: Amnesic mild cognitive impairment, amyloid-beta peptide, biomarkers, clinical trial, clusterin, PharmaCog
project, prodromal Alzheimer’s disease
INTRODUCTION
A current hot-spot of clinical research in
Alzheimer’s disease (AD) deals with the discovery
of sensitive, specific, non-invasive, and cost-effective
biomarkers useful for the diagnosis or the quan-
tification of illness progression from prodromal
stage (amnesic mild cognitive impairment, aMCI)
to dementia stage, featuring severe cognitive deficits
and disability in self-care and autonomy [1]. Accord-
ing to the current guidelines, as reported in Dubois et
al. [1], diagnostic biomarkers of AD include low con-
centration of A42 and high concentration of total tau
(T-tau) or phospho-tau (P-tau) in cerebrospinal fluid
(CSF), or evidence of significant amyloid deposition
and tau aggregation in the brain in maps of positron
emission tomography (PET). On the other hand, topo-
graphic or progression biomarkers of AD measure
atrophy of hippocampus or cerebral cortex, as quanti-
fied in structural magnetic resonance imaging (MRI),
and hypometabolism in posterior cingulate, parietal,
temporal, and hippocampal regions, as measured by
FDG-positron emission tomography (FDG-PET) [1].
Of note, the use of those procedures in AD clinical
practice is relatively limited by invasiveness of the
protocols or high-cost of instruments and exams.
The discovery of reliable blood biomarkers of AD
would be a great improvement, as they are min-
imally invasive, potentially accessible everywhere,
and intrinsically cost-effective. The current state-
of-the-art in the field has been recently reviewed
[2, 3]. Many different biological targets have been
proposed as blood biomarkers of prodromal AD,
as those based on the amyloid- protein precursor
(APP) processing, the molecules related to tangle
pathology coming from tau dysregulation, markers
AU
TH
OR
 C
OP
Y
D. Albani et al. / Plasma Aβ42 as Biomarker of Prodromal Alzheimer’s Disease 39
of neurodegeneration and microglia/astrocyte acti-
vation as neurofilament light (NF-L), neurogranin
(Ng), sTREM2 and YKL-40, or AD-associated pro-
tein accumulation (for instance, -synuclein and
TDP-43), up to microRNA (miRNA) quantification
[2–7]. Unfortunately, literature results are contradic-
tory, probably because of a lack of standardization
in assays and clinical inclusion criteria. In particu-
lar, many studies were centered on the comparison of
healthy controls and AD patients, a choice that might
be a confounding factor for diagnostic or prognostic
purposes [8–13].
Clusterin (apolipoprotein J, CLU) has also been
suggested as candidate plasma biomarker of AD,
based on CLU gene involvement in AD risk and the
availability of several association studies assessing
CSF or plasma CLU level in prodromal dementia
[14–18].
Keeping in mind the above scenario, it is
critical to underscore that some differences in
blood biomarkers between AD patients and age-
matched healthy controls with normal cognition
may be unspecific for disease neuropathology.
In other words, those biomarkers might be
sensitive not only to AD but also to other dis-
orders inducing cognitive deficits in seniors. To
account for this confounding variable, here we
took advantage from the prospective, multi-centric
clinical study named “IMI-PharmaCog-European
ADNI” (http://www.pharmacog.org), where 144
aMCI patients were followed over time with the
collection of clinical, neuropsychological, struc-
tural and functional MRI, electroencephalographic
(rsEEG/ERP), CSF, and blood data. In the present
study, we specifically tested the hypothesis that blood
plasma measured molecules A42, A40, and CLU
may be able to diagnose AD and monitor its progres-
sion (i.e., a period of 18 months) from prodromal
disease stages.
This article is part of a Mini Forum of Journal of
Alzheimer’s disease on PharmaCog/E-ADNI matrix
of biomarkers of prodromal AD in patients with
aMCI.
MATERIALS AND METHODS
Participant clinical features and classification
Participants’ demographics, clinical, and neu-
ropsychological data have been described in recent
PharmaCog/E-ADNI studies. Briefly, 147 aMCI
patients were enrolled in 13 European memory
clinics of the Innovative Medicine Initiative (IMI)
PharmaCog/E-ADNI project. The protocol of this
study was designed in the framework of IMI and
was aimed at improving the pathway of drug discov-
ery in AD, with a main interest in disease-modifying
drugs reducing A42 in the brain in AD patients at
the prodromal stage of aMCI. Inclusion criteria were
age between 55 and 90 years; complaints of mem-
ory loss; Mini-Mental State Examination (MMSE)
score of ≥24; Clinical Dementia Rating score of 0.5;
score on the logical memory test < 1 standard devi-
ation from the age-adjusted mean; 15-item Geriatric
Depression Scale score ≤5; and no neurologic, sys-
temic or psychiatric comorbidity [19, 20]. We applied
the diagnostic criteria for AD suggested by IWG-2
[1] and AA-NIH [21] guidelines. According to these
guidelines, even at prodromal stage, AD is associated
with 1) a reduction of CSF A42 and its increase at
brain level and with 2) an increase of phospho-tau
in both CSF and brain. IWG-2 and AA-NIH guide-
lines state that the diagnosis of AD can be done with
A42 and tau biomarkers even with a single record-
ing session, as AD is considered a progressive disease
[1, 21]. Before study enrollment, each patient gave
signed informed consent in compliance to the guide-
lines of local ethical committees. Data collected and
generated have been always used in anonymous and
aggregated form.
The aMCI patients were classified into two
groups named “positive” (i.e., prodromal AD) and
“negative” (i.e., stable aMCI) based on baseline
CSF A42/P-tau levels as well as apolipopro-
tein E (APOE) 4 genotype [22]. Specifically,
aMCI patients were considered “positive” with CSF
A42/P-tau levels lower than 15.2 for APOE 4 car-
riers and lower than 8.9 for APOE 4 non-carriers,
otherwise “negative”. These cut-offs were obtained
by applying model-based classification methods
(mixture models) [23] on baseline CSF A42/P-tau
distribution, adjusted for APOE 4 genotype.
Blood collection and plasma separation
All procedures involving patients were done after
eligibility check according to inclusion criteria and
informed consent signature. Blood for plasma prepa-
ration was collected by venipuncture at baseline, at
month 12 and 18 during follow-up, resulting in a total
of 3 venipuncture sessions.
Procedures for blood withdrawal and processing
were standardized for all centers. Blood sam-
ples were processed within 1 h from the puncture.
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Briefly, 10 mL of blood were collected into EDTA
tubes of and centrifuged at 1600 g/4◦C/15 min. The
supernatant (plasma) was transferred into a new
polypropylene tube after gentle shaking to avoid gra-
dient effects and divided into aliquots of 250L
in dry ice. Plasma was kept frozen at –80◦C in
temperature-monitored ultra-freezers (–80◦C ± 5◦C)
until required.
Amyloid peptides 40 and 42 (Aβ40, Aβ42) and
clusterin (CLU) ELISA determination
The assessment of plasma A42 and A40 was
done with ELISA kits from Fujirebio (Fujire-
bio, Japan), namely Innotest -amyloid(1-42) (code
81576), in presence of high-sensitivity secondary
antibody conjugate (code 81587), and Innotest
-amyloid(1-40) (code 81585). The limit of detec-
tion (LOD) for the kits were 4.0 and 5.0 pg/mL,
respectively. The assays dynamic ranges were
7.8–1000 pg/mL and 6.8–1000 pg/mL, respectively.
Human clusterin (apolipoprotein J) concentration
in plasma was measured by an ELISA kit (BioVendor
– Laboratornı´ medicı´na a.s., Czech Republic, code
BV53031). The kit limit of detection (LOD), defined
as concentration of analyte giving absorbance higher
than mean absorbance of blank plus three standard
deviations of the absorbance of blank, was 0.5 ng/ml.
The assay dynamic range was from 5 to 160 ng/mL.
Statistical analysis
Statistics was done by SPSS software for descrip-
tive statistics and R software (version 3.4.1) for the
computational analysis based on Linear Mixed Mod-
els. The aMCI participants’ features were compared
by parametric Student’s t-tests or non-parametric
Mann-Whitney’s U-test, depending on Gaussian dis-
tribution and using Chi-square tests for categorical
data. Due to the exploratory nature of the present
study, significance level was set at p < 0.05 [24].
Two different types of Linear Mixed Models
(LMMs, performed by R-package lme4) for repeated
measures were used with all available values of the
plasma biomarkers (A42, A40, A42/A40, and
CLU) and clinical variables. Random intercept and
random slope were considered to account for individ-
ual differences at baseline as well as for individual
change over follow-up. The output of the LMMs
was presented in terms of standardized  coeffi-
cient, corresponding p-value and effect size (pseudo
η2) calculated as ratio of explained variability
of interaction effect on total variability of each
model.
In detail, a first group of LMMs was conducted
to identify plasma measured molecules (dependent
variable) that differently progressed in prodromal AD
compared to stable aMCI patients in the whole aMCI
group. This was performed by adding age, gender,
education, time, group (corresponding to CSF status),
time X group interaction as covariates. Only plasma
measures with significant group X time interaction
were of interest, meaning that they differently pro-
gressed over-time between groups. A second group
of LMMs was conducted to evaluate the associ-
ation between cognitive changes (ADAS-Cog 13,
dependent variable) and peripheral plasma measured
molecules, in the whole group and in prodromal AD
patients only. This was performed by adding age,
gender, time and biomarker as covariates. Plasma
assessed molecules showing a significant effect of
the biomarker factor were of interest, meaning that
they were associated to cognitive decline.
RESULTS
Patients’ features
In the IMI-PharmaCog/E-ADNI study, a cohort of
144 aMCI out of the 147 enrolled patients underwent
CSF standard dementia biomarker evaluation (A42,
T-tau, P-tau) and APOE genotyping. Table 1 summa-
rizes IMI-PharmaCog/E-ADNI cohort demographic
and clinical features. Due to plasma unavailability of
some patients, the number of aMCI patients who were
included for plasma measure assessment was lower
(i.e., 128 aMCI patients). The main demographic and
clinical characteristics of the included patients are
reported in Table 2. In both Tables 1 and 2, after
stratification according to baseline A42/P-tau ratio
values in the CSF as a function of APOE genotype
[22], the aMCI patients were classified as “positive”
(prodromal AD) or “negative”. We also statistically
compared mean values reported in Table 2 to Table 1
in order to exclude a selection bias due to the unavail-
able samples in the plasma analysis. There were no
differences between the “positive” (prodromal AD)
and “negative” aMCI groups (data not shown).
Amyloid peptides 40 and 42 (Aβ40, Aβ42),
clusterin (CLU), and prodromal AD
Figures 1 to 4 summarize the results of an
exploratory statistical analysis about plasma A42,
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Table 1
Clinical and socio-demographic features of amnesic mild cognitive
impairment (aMCI) patients recruited for the IMI-PharmaCog/E-
ADNI study. Patients were stratified as CSF A42/P-tau “positive”
and “negative” according to APOE4-specific cut-offs [22]
“negative” “positive” pa
MCI MCI
(n = 63) (n = 81)
Age, mean (SD) 68.3 (8.4) 69.8 (6.3) 0.208
Sex, F/M, No. 36/27 46/35 1.000
Education, mean (SD) 10.0 (4.3) 11.1 (4.4) 0.115
APOE 4 carriers, No. (%) 3 (5) 63 (78) <0.001
MMSE, mean (SD) 27.1 (1.8) 26.2 (1.8) 0.006
ADAS-Cog13, mean (SD)b,c 19.1 (5.9) 21.6 (8.1) 0.052
CSF biomarkers, mean (SD, pg/mL)
A42 949 (244) 495 (132) <0.001
P-tau 47 (15) 84 (38) <0.001
T-tau 301 (149) 614 (394) <0.001
aParametric t-test (or corresponding non-parametric Mann-
Whitney) for continuous Gaussian (or non-Gaussian) distributed
variables and Chi-square test for categorical data. bRange 0–85,
with 0 as the best score. cInformation was missing for 1 patient.
ADAS-Cog13, Alzheimer Disease Assessment Scale-Cognitive
Subscale, version 13; A42, amyloid- 42; APOE, apolipoprotein
E; CSF, cerebrospinal fluid; P-tau, tau phosphorylated at threonine
181; SD, standard deviation; T-tau, total tau.
Table 2
IMI-PharmaCog/E-ADNI study patients who underwent plasma
assessment
“negative” “positive” pa
MCI MCI
(n = 52) (n = 76)
Age, mean (SD) 68.2 (8.4) 69.5 (5.9) 0.30
Sex, F/M, No. 26/26 43/33 0.46
Education, mean (SD) 10.0 (4.2) 11.2 (4.5) 0.13
APOE 4 carriers, No. (%) 2 (3.8) 61 (80) <0.001
MMSE, mean (SD) 27.0 (1.7) 26.2 (1.8) 0.012
ADAS-Cog13, mean (SD)b 18.8 (5.7) 21.6 (8.1) 0.033
CSF biomarkers, mean (SD, pg/mL)
A42 930 (239) 499 (133) <0.001
P-tau 46 (15) 84 (37) <0.001
T-tau 295 (146) 619 (397) <0.001
aParametric t-test (or corresponding non-parametric Mann-
Whitney) for continuous Gaussian (or non-Gaussian) distributed
variables and by Chi-square test for categorical data. bRange 0–85,
with 0 as the best score. ADAS-Cog13, Alzheimer Disease Assess-
ment Scale-Cognitive Subscale, version 13; A42, amyloid- 42;
APOE, apolipoprotein E; CSF, cerebrospinal fluid; P-tau, tau phos-
phorylated at threonine 181; SD, standard deviation; T-tau, total
tau.
A40, A42/A40 ratio, and CLU in the “positive”
(prodromal AD) and “negative” aMCI groups at
the three recording timepoints (T0, T12, and T18
months). The figures also show the same plasma mea-
sures in aMCI patients as a whole group. Exploratory
univariate statistical tests compared the mean values
between the groups or between timepoints (p < 0.05).
Figure 1 shows the results for plasma A42. There
was no significant mean difference between the two
aMCI groups at any time (p > 0.05). Furthermore,
there was no significant mean difference among the
three timepoints when all aMCI patients were con-
sidered as a whole group (p > 0.05).
Figure 2 plots the results for plasma A40. There
was a marginal significance when comparing T0 level
between the two aMCI groups (p = 0.06), with mean
values slightly lower in the “positive” than the “neg-
ative” group. Furthermore, there was no significant
mean difference among the three timepoints when all
aMCI patients were considered together (p > 0.05).
Figure 3 illustrates the results for plasma
A42/A40 ratio. There was no significant mean dif-
ference between the two aMCI groups at any time
(p > 0.05). Moreover, there was no difference among
the three timepoints when all aMCI patients were
grouped.
Finally, Fig. 4 describes the results for CLU. There
was no significant mean difference between the two
aMCI groups at any time (p > 0.05). In contrast, CLU
increased in all aMCI patients as a whole group over
time, with a significant difference from T0 to both
T12 and T18 (p < 0.001). This difference was com-
mon to the “negative” and “positive” aMCI groups.
To refine the above statistical analysis, we applied
Linear Mixed Models to the plasma measures using
the factors Group (“positive” and “negative” aMCI)
and Time (T0, T12, and T18). Table 3 reports the pro-
portion of variability in plasma measures over time
explained by Time, Group (CSF status as defined
by A42/P-tau), and Time X Group interaction. All
plasma measures considered reported a significant
effect of Time (for A42, p < 0.001; A40, p = 0.009;
A42/A40 ratio, p = 0.006; CLU, p < 001), showing
their changes over time (T0 to T18) regardless of the
group. Conversely, none of those measures showed a
significant “diagnostic” Group effect (p > 0.05).
Noteworthy, there was a significant Time X Group
effect for plasma A42, showing that compared to the
“negative” aMCI group, the “positive” (prodromal
AD) aMCI group was characterized by a significant
decrease of the measure over time (p < 0.05), in line
with the feature of a disease progression biomarker.
Correlation of Aβ40, Aβ42, Aβ42/Aβ40, and
clusterin (CLU) with ADAS-cog13 score
Table 4 reports the results of Linear Mixed Models
testing the correlation over time of plasma measured
molecules (A42, A40, A42/A40 ratio, and CLU)
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Fig. 1. Plasma A42 levels in the IMI-PharmaCog/E-ADNI study. (A) Whole aMCI group over time; (B) Baseline (T0); (C) Assessment after
12 months from T0 (T12); (D) Assessment 18 months from T0 (T18). Data are presented as box-plot, with the upper box line indicating the
3rd quartile, the lower one the 1st quartile and the bold line the median. The single measures are also indicated as empty circles. “Negative”
and “positive” refer to the classification of aMCI according to the APOE-specific cut-offs [22].
with ADAS-Cog13 score. When all aMCI patients
were considered as a whole, there was a signif-
icant association with ADAS-Cog13 score for all
plasma measures (p < 0.003) with the only exception
of A40. This association reflected the increase of
ADAS-Cog13 scores over the follow-up period due
to a progressive cognitive impairment of the whole
population.
When the “positive” (prodromal AD) aMCI group
was considered alone, there was still a significant
association between plasma A42 (p < 0.05) and
ADAS-Cog13 score, thus suggesting a clinical rele-
vance of that measure. The same was true for plasma
A42/A40 ratio (p < 0.05). Instead, no association
was found for A40 alone or CLU (p > 0.05).
DISCUSSION
The IMI-PharmaCog/E-ADNI longitudinal study
aimed at testing candidate biomarkers suitable to
diagnose prodromal AD in aMCI patients and track
disease progression over time (up to 24 months).
As a novelty in the field of biomarker discovery for
aMCI progressing to AD, to overcome the possi-
ble confounding effect of comparing healthy subjects
to cognitively impaired patients, we used a control
group with the same kind of amnesic deficits of the
experimental group. Specifically, we compared blood
plasma biomarkers in aMCI patients “positive” (i.e.,
prodromal AD) versus “negative” classified basing
on their CSF A42/P-tau level and APOE 4 car-
rier status [22]. In the present investigation, we tested
the diagnostic or disease monitoring value of plasma
A42, A40, and CLU in aMCI patients with probable
prodromal AD. Among many other plasma biomarker
candidates, the present ones have obvious links to AD
pathogenic mechanisms and a direct counterpart on
relevant CSF and PET diagnostic measures used in
AD research.
However, the collected plasma and DNA samples
may be suitable for other AD blood biomarker candi-
dates of interest, including a variety of protein, lipid,
and microRNA species, as well as mitochondrial
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Fig. 2. Plasma A40 levels in the IMI-PharmaCog/E-ADNI study. (A) Whole aMCI group over time; (B) Baseline (T0); (C) Assessment 12
months from T0 (T12); (D) Assessment 18 months from T0 (T18). Data are presented as box-plots, with the upper line indicating the 3rd
quartile, the lower one the 1st quartile and the bold line the median. The single measures are also indicated as empty circles. “Negative” and
“positive” refer to the classification of aMCI according to the calculated algorithm, as reported above.
genes or DNA epigenetic modification patterns
[25–32]. They may be evaluated in future studies
carried out in PharmaCog/E-ADNI “positive” and
“negative” aMCI groups.
Concerning the diagnostic value of the assessed
blood biomarker candidates, the present results
showed that plasma A42 was not specifically asso-
ciated with the group of “positive” aMCI patients
(prodromal AD) when the three recordings (base-
line, 12, and 18 months) were considered as a whole.
Furthermore, plasma A42, A42/A40 ratio, and
CLU in all aMCI patients as a whole were correlated
with cognitive status as measured by ADAS-Cog13
score, namely the neuropsychological procedure typ-
ically used in AD clinical trials [33, 34]. These
findings suggest that plasma A42, A42/A40 ratio,
and CLU are clinically relevant for aMCI cogni-
tive status and may partially explain the variance of
the results in previous studies where plasma A42
and A40 (or their ratio) were informative on AD
status, especially when AD patients with dementia
were compared to seniors with intact cognition [8].
Indeed, this association between plasma biomarkers
and AD status was not always confirmed [11, 13].
So large variance of results in previous investiga-
tions might partially depend on cognitive status of
participants in the AD and control groups as well as
disease stage of AD participants. Of course, tech-
nical reasons may also contribute to the observed
variance in previous findings [35, 36]. For example,
the importance of plasma A42 as a biomarker of AD
has been recently re-evaluated thanks to the contri-
bution of Nakamura and colleagues, who measured
plasma A42 with an advanced high-performance
procedure based on immunoprecipitation followed
by mass spectrometry [7]. In light of this improved
protocol, they were able to demonstrate an interest-
ing correlation between plasma A42 measurements
and CSF and PET biomarker counterparts in AD
patients [7]. In addition, Nabers and colleagues devel-
oped an immune-infrared sensor to measure the
secondary structure change of all soluble A pep-
tides in human plasma that correlated to CSF AD
biomarkers and amyloid PET in a cross-sectional
study and was predictive of AD in a prospective
cohort [37].
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Fig. 3. Plasma A42/A40 ratios in the IMI-PharmaCog/E-ADNI study. (A) Whole aMCI group over time; (B) Baseline (T0); (C) Assessment
12 months from T0 (T12); (D) Assessment 18 months from T0 (T18). Data are presented as box-plots, with the upper line indicating the 3rd
quartile, the lower one the 1st quartile and the bold line the median. The single measures are also indicated as empty circles. “Negative” and
“positive” refer to the classification of aMCI as already described.
As for the informative value of the considered
plasma biomarkers on prodromal AD progression, the
present results show that plasma A42 was specif-
ically associated with the “positive” aMCI group
(prodromal AD) as a function of time (i.e., follow-
ups at 12 and 18 months). The prodromal AD patients
showed a specific significant decrease of plasma
A42 over time, which correlated with the dete-
rioration of cognitive performance as revealed by
ADAS-cog13 scores. To our knowledge, this is the
first demonstration that plasma A42 may be used
as a biomarker of prodromal AD progression, tak-
ing into account the confounding variable of aMCI
patients’ cognitive status.
Available literature shows mixed results about
the possible correlation between CSF and plasma
A42. In our study, we checked for this correlation
in “positive” aMCI subjects, finding no evidence of
correlation (data not shown). Indeed, some previous
studies failed in demonstrating a significant relation-
ship [38, 39] while other were successful in finding a
correlation, either positive [8] or negative [40]. Here
we report that compared with the “negative” aMCI
subjects, the “positive” aMCI showed a steeper
longitudinal lowering in the A42 at plasma level
(interaction between Group x Time factors) but
not a lowering considering all recording sessions
as a whole (i.e., no Group factor effect). This out-
come cannot be explained by an effect of different
cognitive deficits in the experimental (“positive”
MCI) and control (“negative” MCI) groups, as both
were MCI (indeed, the condition of MCI might
theoretically be due not only to AD neuropathology
but also other parallel causes affecting cognitive
functions, namely a cerebrovascular disease). A
conclusive explanation of the above results requires
further investigation. We can just speculate that
plasma A42 may be influenced not only by the brain
amyloidosis but also by the interaction between such
process and others related to AD (e.g., tauopathy and
neurodegeneration). However, any interpretation of
the results should take into account that our study
focused on a limited time of follow-up (i.e., until
18–24 months) and that CSF could be collected
only at baseline and after 18 months. Therefore, our
findings are a proof-of-concept to be cross-validated
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Fig. 4. Plasma clusterin (CLU) in the IMI-PharmaCog/E-ADNI study. (A) Whole aMCI group over time; (B) Baseline (T0); (C) Assessment
12 months from T0 (T12); (D) Assessment 18 months from T0 (T18). Data are presented as box-plots, with the upper line indicating the 3rd
quartile, the lower one the 1st quartile and the bold line the median. The single measures are indicated as empty circles. For “negative” and
“positive” aMCI classification, see above. ∗∗∗p < 0.001 versus T0, ANOVA and Tukey’s post-hoc test.
Table 3
Linear Mixed Models for the analysis of selected plasma molecules in aMCI patients stratified as “positive”, as prodromal AD, and
“negative” as a control group, according to cut-offs of CSF A42/P-tau [22]. The model included age, sex, baseline MMSE score, Time,
Group (A42/P-tau status), and Time X Group interaction as predictors. Significant (p < 0.05) effects are shown in bold
Measure Time Group Time X Group
(dependent Std  p Std  p Std  p Pseudo η2
variable) (Effect size)
A42 0.209 <0.0001 0.011 0.937 0.151 0.048 0.25
A40 0.206 0.009 0.142 0.286 0.036 0.815 0.01
A42/A40 0.193 0.0006 0.062 0.725 0.147 0.326 0.01
CLU 0.462 <0.001 0.085 0.562 0.062 0.663 0.01
Std , standardized  coefficient of Linear Mixed Model; CLU, clusterin (apolipoprotein J).
with a longitudinal study in which A42 in the CSF
and plasma are systematically recorded in positive
MCI subjects over time.
The second plasma biomarker investigated in the
present study was clusterin (apolipoprotein J, CLU),
based on the promising literature addressing the role
of CLU in blood-based early AD diagnosis. In fact,
it was reported that CLU levels are elevated in brain,
CSF, and plasma of AD patients with dementia and
MCI [41]. Moreover, CLU is functionally associated
with amyloid species, and many genetic association
studies have confirmed its role as a predisposing fac-
tor for AD [42–45]. Despite these considerations, we
were unable to show a significant value of CLU nei-
ther in prodromal AD diagnosis nor in the disease
progression. There was, however, a slight increase
of plasma CLU over time both in “negative” and
“positive” aMCI groups, suggesting that this blood
biomarker may track the progression of brain disor-
ders but not specifically for AD. It can be speculated
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Table 4
Longitudinal Mixed Model Analysis of the association between cognitive decline
(ADAS-Cog 13, dependent variable) and peripheral circulating molecules in the
whole group and in the A42/P-tau positive MCI patients [22]. Significant
(p < 0.05) effects are shown in bold
Measure Whole MCI group A42/P-tau positive MCI
(independent patients
variable) Biomarker Biomarker
Standardized  p Standardized  p
A42 0.267 0.003 0.225 0.046
A40 0.047 0.346 0.079 0.150
A42/A40 0.225 0.002 0.226 0.016
CLU 0.149 0.002 0.096 0.092
CLU, clusterin (apolipoprotein J).
that this blood biomarker may have a slower variation
with disease onset and progression in comparison to
plasma A42, and increased amyloid burden may be
required to reveal robust CLU differential expression
in brain or in the periphery. In the present experimen-
tal design, the plasma follow-up time (18 months)
may be too limited to conclusively demonstrate an
AD-specific variation of CLU longitudinally.
In conclusion, we suggest that after the diagnosis of
aMCI according to criteria based on CSF A42 low-
ering and P-tau increase [1, 21], also plasma A42
measured with standard ELISA procedure may be
sensitive to prodromal AD progression and cognitive
impairment. Instead, we did not confirm a diagnostic
value of plasma A42, at least at that prodromal stage.
We are confident that in a short-term period other
studies may cross-validate our results, also taking
advantage from recent technological advancements
in the assessment of plasma A42 [7], and we propose
to speed-up plasma A42 assay translation to clinical
setting. Finally, our results on plasma A42 may be
integrated by future studies that systematically inves-
tigate the relationship between CSF versus plasma
phospho-tau and total tau, considering the remarkable
steps forward in the measurement of those biomarkers
[46].
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